Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Inspire Phase III dry eye data

ISPH said that in a placebo-controlled Phase IIIb trial in 222 dry eye patients, 2% diquafosol tetrasodium ( INS365) ophthalmic drops did not

Read the full 235 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE